A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide

BACKGROUND: Glioblastoma (GBM) is the most common primary, malignant brain tumor in adults and has a poor prognosis. The median progression-free survival (mPFS) of newly diagnosed GBM is approximately 6 months. The recurrence rate approaches 100%, and the case-fatality ratio approaches one. Half the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bota, Daniela A., Taylor, Thomas H., Lomeli, Naomi, Kong, Xiao-Tang, Fu, Beverly D., Schönthal, Axel H., Singer, Samuel, Blumenthal, Deborah T., Senecal, Frank M., Linardou, Helena, Rokas, Evangelos, Antoniou, Dimitris G., Schijns, Virgil E. J. C., Chen, Thomas C., Elliot, Joseph, Stathopoulos, Apostolos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273968/
https://www.ncbi.nlm.nih.gov/pubmed/35837107
http://dx.doi.org/10.3389/fonc.2022.934638

Ejemplares similares

Ejemplares similares